On 18 June 2024, Justice Burley delivered a decision regarding documentary discovery in the long running dispute between Pfizer (Pfizer Ireland Pharmaceuticals and Pfizer Australia) and four of its competitors over AU2005280034 for the “Production of polypeptides” (the Pfizer Patent).
On 18 June 2024, Justice Burley delivered a decision regarding documentary discovery in the long running dispute between Pfizer (Pfizer Ireland Pharmaceuticals and Pfizer Australia) and four of its competitors over AU2005280034 for the “Production of polypeptides” (the Pfizer Patent).
Aflibercept 23 September 2024 | Positive 52-Week, Ph 3 Results for Celltrion’s Aflibercept Biosimilar On 23 September...
Aflibercept 19 September 2024 | EU | Sandoz & Samsung Bioepis/Biogen Aflibercept Biosimilars Recommended in Europe...
Aflibercept 13 September 2024 | KR | Alteogen Submits Application for Biosimilar Aflibercept in Korea On 13 September...
Adalimumab 1 September 2024 | AU | Pfizer’s Biosimilar Adalimumab PBS-Listed in Australia On 1 September 2024, the PBS...
CQMS has successfully opposed ESCO Group’s (ESCO) patent application AU 2018201726 (‘726) on the grounds of lack of support and sufficiency. We previously reported on an opposition between the same parties for a related patent family member AU 2018201710 (‘710). As with that case, the Delegate in the present opposition exercised his authority under section 60(3) of the Patents Act 1990 and raised the additional opposition ground of inutility, which was not asserted by CQMS.
16 August 2024 | AU | Janssen Sues Samsung Bioepis for Patent Infringement in Australian Court On 16 August 2024,...
9 August 2024 | Sandoz Reports Q2/24 and Half Year Financial Results - 37% Biosimilar Growth On 9 August 2024, Sandoz...
2 August 2024 | AU | Novo Nordisk Launches Wegovy® (Semaglutide) in Australia On 2 August 2024, Australia’s...
26 July 2024 | EU | New Indication Alert: EU Approves AbbVie’s Skyrizi® (Risankizumab) for UCOn 26 July 2024, AbbVie...
19 July 2024 | EU | Gedeon Richter’s EU Denosumab Biosimilars AcceptedOn 19 July 2024, Gedeon Richter announced that...
12 July 2024 | HK | IS | Approval Alert: Eisai’s Leqembi® (Lecanemab) Approved in Hong Kong and Israel for Alzheimer's...
7 July 2024 | IN | Approval Alert: Zydus Life Sciences’ Biosimilar Nivolumab Approved in IndiaOn 7 July 2024, Medical...
28 June 2024 | Shanghai Henlius Biotech Completes Phase 1 Trials for Daratumumab Biosimilar Shanghai Henlius Biotech...